Mark Verratti's Insider Trades & SAST Disclosures
Mark Verratti's most recent trade in Myriad Genetics, Inc. was a trade of 105,785 Performance-Based Restricted Stock Units done . Disclosure was reported to the exchange on April 30, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Mark Verratti.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Myriad Genetics, Inc. | Mark S. Verratti | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2025 | 105,785 | 105,785 | - | - | Performance-Based Restricted Stock Units | |
| Myriad Genetics, Inc. | Mark S. Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.08 per share. | 14 Apr 2025 | 1,085 | 382,911 (0%) | 0% | 8.1 | 8,767 | Common Stock |
| Myriad Genetics, Inc. | Mark S. Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.01 per share. | 22 Mar 2025 | 3,623 | 386,697 (0%) | 0% | 10.0 | 36,266 | Common Stock |
| Myriad Genetics, Inc. | Mark S. Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.98 per share. | 22 Mar 2025 | 1,605 | 383,996 (0%) | 0% | 10.0 | 16,018 | Common Stock |
| Myriad Genetics, Inc. | Mark S. Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.01 per share. | 22 Mar 2025 | 1,366 | 390,320 (0%) | 0% | 10.0 | 13,674 | Common Stock |
| Myriad Genetics, Inc. | Mark S. Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.98 per share. | 22 Mar 2025 | 1,096 | 385,601 (0%) | 0% | 10.0 | 10,938 | Common Stock |
| Myriad Genetics, Inc. | Mark S. Verratti | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 99,227 | 401,262 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Mark S. Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.07 per share. | 13 Mar 2025 | 5,847 | 395,415 (0%) | 0% | 10.1 | 58,879 | Common Stock |
| Myriad Genetics, Inc. | Mark S. Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.07 per share. | 13 Mar 2025 | 3,729 | 391,686 (0%) | 0% | 10.1 | 37,551 | Common Stock |
| Myriad Genetics, Inc. | Mark S. Verratti | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 12,758 | 302,035 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.37 per share. | 09 Oct 2024 | 5,004 | 289,277 (0%) | 0% | 24.4 | 121,947 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.37 per share. | 09 Oct 2024 | 3,359 | 294,281 (0%) | 0% | 24.4 | 81,859 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.64 per share. | 21 Sep 2024 | 1,075 | 297,640 (0%) | 0% | 27.6 | 29,713 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.55 per share. | 14 Apr 2024 | 1,076 | 298,715 (0%) | 0% | 19.6 | 21,036 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 1,661 | 301,375 (0%) | 0% | 22.2 | 36,941 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 1,648 | 303,036 (0%) | 0% | 22.2 | 36,652 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 1,584 | 299,791 (0%) | 0% | 22.2 | 35,228 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 58,631 | 308,370 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.16 per share. | 14 Mar 2024 | 3,686 | 304,684 (0%) | 0% | 21.2 | 77,996 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.27 per share. | 14 Apr 2023 | 703 | 262,704 (0%) | 0% | 22.3 | 15,656 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.72 per share. | 24 Mar 2023 | 1,586 | 263,407 (0%) | 0% | 23.7 | 37,620 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.72 per share. | 24 Mar 2023 | 1,083 | 264,993 (0%) | 0% | 23.7 | 25,689 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.91 per share. | 22 Mar 2023 | 1,351 | 266,076 (0%) | 0% | 22.9 | 30,951 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 39,405 | 267,427 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.62 per share. | 09 Oct 2022 | 5,006 | 228,022 (0%) | 0% | 19.6 | 98,218 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.62 per share. | 09 Oct 2022 | 3,360 | 233,028 (0%) | 0% | 19.6 | 65,923 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.69 per share. | 25 Sep 2022 | 2,793 | 238,681 (0%) | 0% | 18.7 | 52,201 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.41 per share. | 25 Sep 2022 | 2,293 | 236,388 (0%) | 0% | 18.4 | 42,214 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.20 per share. | 21 Sep 2022 | 702 | 241,474 (0%) | 0% | 20.2 | 14,180 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.89 per share. | 25 Aug 2022 | 1,031 | 242,176 (0%) | 0% | 24.9 | 25,662 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2022 | 10,000 | 243,207 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Mark Verratti | President, Mental Health | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.32 per share. | 24 Mar 2022 | 1,584 | 233,207 (0%) | 0% | 25.3 | 40,107 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | President, Mental Health | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.32 per share. | 24 Mar 2022 | 1,082 | 234,791 (0%) | 0% | 25.3 | 27,396 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | President, Mental Health | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2022 | 19,238 | 235,873 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Mark Verratti | President, Mental Health | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 22,616 | 216,635 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Mark Verratti | President, Myriad Neuroscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.88 per share. | 09 Oct 2021 | 4,991 | 194,019 (0%) | 0% | 30.9 | 154,122 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | President, Myriad Neuroscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.88 per share. | 09 Oct 2021 | 3,349 | 199,010 (0%) | 0% | 30.9 | 103,417 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | President, Myriad Neuroscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.31 per share. | 25 Sep 2021 | 6,746 | 205,873 (0%) | 0% | 33.3 | 224,709 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | President, Myriad Neuroscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.31 per share. | 25 Sep 2021 | 3,514 | 202,359 (0%) | 0% | 33.3 | 117,051 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | President, Myriad Neuroscience | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Sep 2021 | 46,571 | 212,619 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Mark Verratti | President, Myriad Neuroscience | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Sep 2021 | 10,000 | 166,048 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Mark Verratti | President, Myriad Neuroscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.81 per share. | 25 Aug 2021 | 1,082 | 156,048 (0%) | 0% | 34.8 | 37,664 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | President, Myriad Neuroscience | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2021 | 15,441 | 157,130 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Mark Verratti | President Assurex Health Inc. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Oct 2020 | 31,258 | 141,689 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Mark Verratti | President Assurex Health Inc. | Sale or transfer of securities back to the company at price $ 13.04 per share. | 30 Sep 2020 | 725 | 110,431 (0%) | 0% | 13.0 | 9,454 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | President Assurex Health Inc. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Sep 2020 | 32,800 | 119,326 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Mark Verratti | President Assurex Health Inc. | Sale or transfer of securities back to the company at price $ 12.44 per share. | 24 Sep 2020 | 2,897 | 113,532 (0%) | 0% | 12.4 | 36,039 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | President Assurex Health Inc. | Sale or transfer of securities back to the company at price $ 12.44 per share. | 24 Sep 2020 | 2,897 | 116,429 (0%) | 0% | 12.4 | 36,039 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | President Assurex Health Inc. | Sale or transfer of securities back to the company at price $ 12.44 per share. | 24 Sep 2020 | 2,376 | 111,156 (0%) | 0% | 12.4 | 29,557 | Common Stock |
| Myriad Genetics, Inc. | Mark Verratti | President Assurex Health Inc. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2020 | 7,467 | 86,526 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges